Welcome to our dedicated page for Bone Biologics SEC filings (Ticker: BBLG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bone Biologics Corp filings document regulatory disclosures for a clinical-stage orthobiologic developer focused on rhNELL-1 and NB1 in spine fusion markets. Current reports on Form 8-K include Regulation FD updates on corporate, scientific, and operational milestones, along with exhibits tied to public communications.
The company’s filings also cover capital-structure activity, including common stock, warrants, shelf registration statements on Form S-3, prospectus supplements, and at-the-market offering arrangements. These disclosures describe financing tools, securities covered by registration documents, legal opinions, and related material-event reporting.
Bone Biologics Corporation is registering up to 6,464,792 shares of common stock for resale by selling stockholders, all issuable upon exercise of outstanding warrants from a July 9, 2026 private placement and related placement agent warrants. The company will not receive proceeds from resale of these shares, but could receive approximately $6.2 million if all warrants are exercised for cash.
Shares outstanding were 1,810,380 as of July 16, 2026 and would be 8,275,172 assuming full warrant exercise. The registered shares equal about 357% of current outstanding stock, and large resales could pressure the share price. Bone Biologics is a clinical-stage medical device company developing NB1, a NELL-1/demineralized bone matrix fusion device for lumbar spinal fusion, with an ongoing pilot study in up to 30 subjects in Australia. The company has a going concern explanatory paragraph in its 2025 audit opinion and relies on additional capital, including potential warrant exercise proceeds, to fund trials, patents, and working capital.
Bone Biologics Corporation provided a mid-2026 shareholder update covering financing, clinical progress and manufacturing readiness for NB1, its rhNELL-1-based bone graft candidate for spinal fusion. In July 2026, the company completed a private placement with a single healthcare-focused institutional investor, generating approximately $3.0 million in gross proceeds before fees.
The financing included Series F and Series G warrants that could deliver up to approximately $6.0 million in additional gross proceeds if fully exercised for cash. Bone Biologics believes this capital extends its operating runway through Q2 2027 to support clinical trials, patent portfolio work and general operations. The company continues its first-in-human NB1 pilot study and expects to complete enrollment by year-end 2026. In May 2026, the validated shelf life of the rhNELL-1 protein was extended to 29 months, supporting manufacturing and supply-chain planning.
Bone Biologics Corporation is registering up to 6,464,792 shares of common stock for resale by existing security holders. All of these shares are issuable upon exercise of outstanding warrants, including 6,338,031 shares tied to a July 9, 2026 private placement and 126,761 placement agent warrant shares. The company will not receive proceeds from any resale of shares by the selling stockholders, but could receive approximately $6.2 million in gross proceeds if all warrants are exercised for cash, at exercise prices ranging from $0.001 to $1.775 per share. Shares outstanding were 1,810,380 as of July 16, 2026; assuming full cash exercise of the registered warrants, shares outstanding would rise to 8,275,172. The company is a clinical-stage medical device developer focused on NELL-1/DBM bone-regeneration products for spinal fusion and other orthopedic uses and currently carries an auditor “going concern” explanatory paragraph, reflecting the need for additional capital to fund operations and clinical trials.
Bone Biologics Corporation postponed its 2026 annual meeting of stockholders, originally set for August 11, 2026, to September 28, 2026 at 11:30 a.m. Eastern Time at its Burlington, Massachusetts offices.
The Board plans to file a Definitive Proxy Statement on Schedule 14A including an additional proposal and concluded more time is needed for stockholders to review materials. The new record date is August 6, 2026, and the deadline for stockholder nominations or other business is July 26, 2026.
Bone Biologics Corporation entered into a private placement with a single institutional investor, raising gross proceeds of approximately $3.0 million and net proceeds of about $2.7 million. The deal includes 2,112,677 pre-funded warrants and accompanying Series F and Series G warrants to purchase up to a total of 6,338,031 shares of common stock at $1.42 per share, subject to ownership caps of 4.99% or 9.99%.
The Series F warrants have a five-year term and the Series G warrants have an 18‑month term, each starting from the later of stockholder approval and effectiveness of a resale registration statement. If all investor warrants are exercised for cash, the Company could receive additional gross proceeds of about $6.0 million. Placement agent H.C. Wainwright & Co. received cash fees, expense reimbursements, and warrants to purchase 126,761 shares. The Company plans to use proceeds for clinical trials, patent portfolio maintenance, working capital, and general corporate purposes.
Bone Biologics Corporation has called its 2026 Annual Meeting of Stockholders for August 11, 2026 at its Burlington, Massachusetts headquarters. Shareholders are being asked to elect four directors, approve on an advisory basis executive officer compensation, and ratify Weinberg & Company, P.A. as independent auditor for 2026.
Holders of 1,795,260 shares of common stock as of June 12, 2026 may vote by internet, telephone, mail or in person. The board recommends voting “FOR” all director nominees and “FOR” the say-on-pay and auditor ratification proposals. The proxy also details executive and director pay, performance-based bonuses, stock option grants and audit fees.
Bone Biologics Corporation reported no revenue and a net loss of $765,988 for the three months ended March 31, 2026, an improvement from a $1,017,092 loss a year earlier. Research and development spending fell to $141,597 as clinical trial timing shifted, while general and administrative costs rose modestly to $663,457.
Cash was $4,530,040 at March 31, 2026, down from $5,334,322 at year-end, and operating cash outflow was $804,282. Management estimates operating expenditures of $5.4 million over the next twelve months and expects existing cash to fund operations into the fourth quarter of 2026, but the filing states there is “substantial doubt” about the company’s ability to continue as a going concern without additional financing.
Bone Biologics Corporation is updating its at-the-market equity offering program to permit sales of up to $1,064,000 of common stock through H.C. Wainwright & Co. as sales agent under an existing sales agreement. These potential sales are covered by a prospectus supplement dated March 13, 2026, tied to the company’s effective Form S-3 shelf registration statement. The company previously sold approximately $1.7 million of common stock under the same sales agreement using an earlier shelf registration, which is no longer effective. A legal opinion regarding the validity of the shares covered by the new prospectus supplement is filed as an exhibit.